Background: A woman's candidacy for Rh immune globulin depends on whether her blood type is Rh-positive (D antigen-positive) or Rh-negative (D antigen-negative). New molecular blood-typing methods have identified variant D antigens, which may be reported as Rh-positive or Rh-negative depending on the laboratory method. We describe a case illustrating the effect of the new laboratory methods on a woman's candidacy for Rh immune globulin and present recommendations for interpreting the new test results.

Case: A 40-year-old woman presented for management of her third pregnancy. During her first pregnancy, she was typed as Rh-positive ("D") and did not receive Rh immune globulin. During her second pregnancy, she was typed as Rh-negative, in accordance with revised Rh-typing procedures. Anti-D antibody was detected. During her third pregnancy, she was genotyped as a partial D antigen, which was reported as Rh-negative.

Conclusion: Revisions in laboratory procedures for Rh typing may present as a change in the Rh blood type of pregnant women-and as a change in their eligibility for Rh immune globulin.

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0b013e31823f6f76DOI Listing

Publication Analysis

Top Keywords

immune globulin
16
blood type
12
laboratory procedures
8
woman's candidacy
8
candidacy immune
8
third pregnancy
8
pregnancy typed
8
laboratory
4
procedures blood
4
type changes
4

Similar Publications

An Update on Multi-System Inflammatory Syndrome in Children.

Curr Rheumatol Rep

January 2025

Division of Rheumatology, Department of Pediatrics, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI, 02903, USA.

Purpose: To summarize the latest research on the epidemiology, pathogenesis, diagnosis, and treatment of multisystem inflammatory syndrome in children (MIS-C).

Recent Findings: The epidemiology of MIS-C has been dynamic since its initial description. The pathogenesis remains poorly understood.

View Article and Find Full Text PDF

Functional characterization of novel anti-DEFA5 monoclonal antibody clones 1A8 and 4F5 in inflammatory bowel disease colitis tissues.

Inflamm Res

January 2025

Department of Biochemistry, Cancer Biology, Neuroscience, and Pharmacology, School of Medicine, Meharry Medical College, 1005 D.B. Todd Jr. Blvd, Nashville, TN, USA.

Background: The aberrant expression of α defensin 5 (DEFA5) protein in colonic inflammatory bowel diseases (IBDs) underlies the distinct pathogenesis of Crohn's colitis (CC). It can serve as a biomarker for differentiating CC from Ulcerative colitis (UC), particularly in Indeterminate colitis (IC) cases into UC and CC. We evaluated the specificity of commercially available anti-DEFA5 antibodies, emphasizing the need to further validate their appropriateness for a given application and highlighting the necessity for novel antibodies.

View Article and Find Full Text PDF

Hepatitis B virus (HBV) infection is a major global health concern, with liver transplantation (LT) serving as a critical treatment for end-stage liver disease caused by HBV. However, the risk of HBV reinfection after LT remains significant, necessitating effective prophylaxis. Today, the combination of hepatitis B immune globulin (HBIG) and high-barrier nucleos(t)ide analogues (NUCs) is the standard of care for preventing HBV recurrence post-LT but concerns about the cost of HBIG and access to high-barrier NUCs have led to a reduction in the use, dose, and duration of HBIG in recent years.

View Article and Find Full Text PDF

Direct repeat region 3' end modifications regulate Cas12a activity and expand its applications.

Nucleic Acids Res

January 2025

Guangdong Provincial Key Laboratory of Digestive Cancer Research, Digestive Diseases Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong 518107, P.R. China.

CRISPR-Cas12a technology has transformative potential, but as its applications grow, enhancing its inherent functionalities is essential to meet diverse demands. Here, we reveal a regulatory mechanism for LbCas12a through direct repeat (DR) region 3' end modifications and de-modifications, which can regulate LbCas12a's cis- and trans-cleavage activities. We extensively explored the effects of introducing phosphorylation, DNA, photo-cleavable linker, DNA modifications at the DR 3' end on LbCas12a's functionality.

View Article and Find Full Text PDF

Enzyme-linked immunosorbent spot analysis is frequently used to investigate immune responsiveness during clinical trials. However, ELISpot classically utilizes peripheral blood mononuclear cell isolates from whole blood, requiring relatively high blood draw volumes and removing both granulocytes and bound drug. Here, we describe a novel protocol whereby CD45 cells are magnetically isolated from human whole blood and co-incubated with serum isolated from the same subject.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!